Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours
João M. Fernandes Neto(The Netherlands Cancer Institute), René Bernards(The Netherlands Cancer Institute)
Cited by 91
Related Papers
Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence
|Nature Cell Biology|2006|610
The Cancer SENESCopedia: A delineation of cancer cell senescence
|Cell Reports|2021|200
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
|International Journal of Cancer|2014|75